NCT05653271 - ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions

B-cell LymphomaNon Hodgkin LymphomaDLBCLPrimary Mediastinal Large B Cell LymphomaMarginal Zone LymphomaFollicular LymphomaBurkitt LymphomaHigh-grade B-cell Lymphoma

Interventions

DRUG

Cyclophosphamide

Lymphodepleting agent

DRUG

Fludarabine

Lymphodepleting agent

DRUG

ACE1831

Allogeneic gamma delta T (gdT) cell therapy

DRUG

Obinutuzumab

Anti-CD20 monoclonal antibody

Trial Locations (13)

30322

RECRUITING

Emory University, Atlanta

32804

RECRUITING

AdventHealth Orlando, Orlando

40207

RECRUITING

Norton Cancer Institute, Louisville

46202

TERMINATED

Indiana University Simon Comprehensive Cancer Center, Indianapolis

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong

RECRUITING

Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung City

RECRUITING

Ministry of Health and Welfare Shuang-Ho Hospital, New Taipei City

RECRUITING

Tamsui MacKay Memorial Hospital, New Taipei City

RECRUITING

Taichung Veterans General Hospital, Taichung

RECRUITING

National Cheng Kung University Hospital, Tainan City

RECRUITING

National Taiwan University Hospital, Taipei

RECRUITING

Linkou Chang-Gung Memorial Hospital, Taoyuan